Key Drivers
- High liquidity
- No revenue
- Persistent cash burn
AIAI Summary
Enliven has shifted from a binary early‑stage risk to a well‑capitalized, event‑driven growth story where ELVN‑001's upcoming Phase‑3 path (and 2026 catalysts) now drive valuation rather than solvency concerns. Monitor for a clearly funded Phase‑3 start, any partnership/commercialization commitments, and signs of burn‑rate acceleration or delayed timelines—each will be the immediate trigger for significant upside or sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •No revenue
- •Persistent cash burn
ELVN is a well‑capitalized, virtually debt‑free company with substantial cash/investments (~$462.6M) and high liquidity but no FY2025 revenue, sustained operating losses and negative cash flow that undermine its premium market valuation.
Price Behavior
Key Price Behavior Insights:
- •Short-term uptrend
- •28.0–28.8 support
- •30.70 resistance
Over the last month the stock has trended up (from $26.02 to $29.02, ~11%) but remains capped by resistance at $30.70 with primary support around $28.00–$28.80 and a lower floor at $26.02.
~11% rise from $26.02 to $29.02 over last month with a moderate ~16–17% intraperiod range
Sentiment & News
Key News Insights:
- •Investor outreach
- •Routine reporting
- •No new milestones
Enliven synchronized an investor-focused fireside chat and its Q4/FY2025 earnings release to emphasize transparent, routine investor communications with no new pipeline or partnership disclosures.
The coordinated cadence supports steady investor relations but is unlikely to materially change the stock absent clinical or strategic news
Similar Companies in Healthcare
Other companies in the same sector with AI ratings